Delcath(DCTH)

Search documents
Delcath(DCTH) - 2023 Q4 - Annual Results
2024-03-26 11:48
Exhibit 99.1 Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY – March 26, 2024, Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023. Recent Busin ...
Delcath Systems Closes $7 Million Private Placement
Prnewswire· 2024-03-20 12:15
NEW YORK, March 20, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, confirmed the closing of the previously announced private placement with certain accredited investors comprised of existing investors, Delcath Executives and members of its Board of Directors, for a private placement transaction (the "Private Placement"). Delcath issued and sold 876,627 shares of its common stock (the "Comm ...
Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call
Prnewswire· 2024-03-19 13:00
NEW YORK, March 19, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 26, 2024, at 8:30 AM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023 and provide a business update. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call ...
Delcath Systems Appoints Martha S. Rook as Chief Operating Officer
Prnewswire· 2024-03-18 21:20
NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook, Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process developme ...
Delcath Systems Announces $7 Million Private Placement
Prnewswire· 2024-03-15 12:20
NEW YORK, March 15, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited investors comprised of existing investors, Delcath Executives and members of its Board of Directors, for a private placement transaction (the "Private Placement"). Delcath will issue and sell 876,627 shares of its common stock ( ...
Delcath Systems to Participate in Upcoming Investor Conferences
Prnewswire· 2024-03-08 14:00
NEW YORK, March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that Company management will be attending the following upcoming investor conferences: Leerink Partners Global Biopharma Conference Date: March 13, 2024Location: Miami Beach, FL 36th Annual ROTH ConferenceDate: March 18 - 19, 2024Location: Dana Point, CA Management is scheduled to host one-on-one meetings thr ...
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
Prnewswire· 2024-02-22 22:00
NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company has launched a Healthcare Setting Locator (Locator) on the hepzatokit.com website. Potential patients, caregivers, and healthcare providers may use the Locator to identify healthcare settings, offering treatment with the HEPZATO KIT. Sites included on the Locator are accepting inquiries from ...
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Prnewswire· 2024-02-16 22:00
NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in January 2024. The grant totaled the right to purchase an aggregate of 50,000 shares of the ...
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024
Prnewswire· 2024-01-31 13:00
NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Centers for Medicare & Medicaid Services ("CMS") has established a permanent and product-specific J-code (J9248) for HEPZATO. The J-code will become effective on April 1, 2024. J-codes are a form of Healthcare Common Procedure Coding System Level II identifiers used by payors to streamline the billin ...
Delcath(DCTH) - 2023 Q3 - Earnings Call Transcript
2023-11-14 03:07
Delcath Systems Inc. (NASDAQ:DCTH) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants David Hoffman - General Counsel, Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, U.S. Interventional Oncology Conference Call Participants William Maughan - Canaccord Genuity Scott Henry - ROTH Capital Yale Jen - Laidlaw & Co. Operator Good day, and welcome to the Delcath Systems Reports Third Quarter Fiscal Year 2023 Financial Results ...